Peru vs Senegal: Average cost of drugs for extensively drug-resistant tuberculosis
Peru
3,884 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Peru rank
18th
Senegal rank
20th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Peru
- Senegal
How they compare
Peru currently reports 3,884 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal, a difference of 456 constant 2022 US$.
That makes Peru's figure about 1.1 times Senegal's.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Senegal ahead.
Peru ranks 18th and Senegal ranks 20th of 56 countries.
Across the 2 decades both report, Peru averaged higher in 1 and Senegal in 1.
Head to head by decade
| Decade | Peru | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,100 constant 2022 US$ | 5,308 constant 2022 US$ | 208 constant 2022 US$ | Senegal |
| 2020s | 5,925 constant 2022 US$ | 2,890 constant 2022 US$ | 3,034 constant 2022 US$ | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Peru or Senegal?
- Peru, at 3,884 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Peru and Senegal?
- 456 constant 2022 US$, with Peru ahead.
- How many years of comparable data are there for Peru and Senegal?
- 5 years are reported by both, from 2018 to 2024.
- How do Peru and Senegal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Peru ranks 18th and Senegal ranks 20th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.